Researchers make incredible energy breakthrough using 'liquid air': 'We believe our findings justify the continued exploration'
Renewable energy sources, like solar and wind, provide alternatives to dirty energy, and their increased use has sparked research.
One team from the Massachusetts Institute of Technology and Norwegian University of Science and Technology researched a method for storing renewable energy called liquid air energy storage (LAES), Tech Xplore reported. The team studied the technology and its economic viability, discovering it is efficient and cost-effective.
This discovery proves promising since the use of renewable energy is rising. Renewables produced about 21% of the electricity in the U.S. in 2023, while nearly 90% of new electricity capacity came from renewables in the first nine months of 2024. Solar was the fastest-growing source of electricity in the U.S. last year, and wind power surpassed coal power.
However, electricity generation from resources like solar or wind depends on how sunny or windy it is, Tech Xplore explained. Storing these resources when they're abundant enables us to use them when they're not, and energy storage is critical to transition to renewable energy and away from dirty energy. That's where LAES comes into play.
LAES works by charging, storing, and discharging energy, according to Tech Xplore. The LAES system charges when energy supply exceeds demand, and the system intakes and liquefies air. This liquefied air is stored until needed, then it is heated back into a gas, which produces electricity. The system completes this process without additional energy, making it clean. It also does not rely on rare or expensive materials and can be built almost anywhere, Tech Xplore stated.
Since it utilizes available materials, constructing the LAES system is cost-effective. The researchers also studied the economic viability of operating the system, measuring its net present value across 18 U.S. regions under eight decarbonization scenarios. They found Texas and Florida to be the best markets for the system under all scenarios, while subsidies for the system improved its NPV across all regions.
The researchers also measured the levelized cost of storage — the cost of storing each unit of energy — discovering that LAES cost about $60 per megawatt-hour regardless of decarbonization scenario. This cost makes LAES more affordable than other energy storage systems, such as lithium-ion battery storage or pumped hydro storage.
While LAES is technologically feasible, its economic feasibility will determine its future. The team of researchers stressed the need for further development of the technology amidst the shifting energy landscape.
"This is why the story of liquid air storage is far from over. We believe our findings justify the continued exploration of LAES as a key energy storage solution for the future," MIT doctoral candidate and researcher Shaylin Cetegen said.
Should the government be paying us to upgrade our homes?
Definitely
Depends on how much it costs
Depends on what it's for
No way
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
16 minutes ago
- CNN
Trump tells CNN he's ‘not even thinking about Elon' and won't speak to him ‘for a while'
President Donald Trump told CNN on Friday he is 'not even thinking about' billionaire Elon Musk and won't be speaking to him in the near future. 'I'm not even thinking about Elon. He's got a problem. The poor guy's got a problem,' Trump told CNN's Dana Bash. The comments come after a day Trump and Musk traded barbs on social media as their relationship deteriorated in spectacular public fashion. Trump said Thursday he was 'very disappointed' with the tech billionaire for criticizing his massive tax and spending cuts package while Musk fired back that 'Trump would have lost the election' without him. In a brief phone call, Trump talked about the forthcoming jobs report, inflation and gas prices. Asked if he had a call with Musk, the president responded: 'No. I won't be speaking to him for a while I guess, but I wish him well.' As the two powerful onetime friends duked it out online on Thursday, their shared allies sought to quietly broker a truce, CNN previously reported. Musk, for his part, appeared open to a thaw. 'You're not wrong,' Musk responded to a post from billionaire investor Bill Ackman, who wrote on X: 'I support @realDonaldTrump and @elonmusk and they should make peace for the benefit of our great country. We are much stronger together than apart.'
Medscape
25 minutes ago
- Medscape
Which Tx Combo Is Best for HER2+ Breast Cancer?
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other interim results of the phase 3 DESTINY-Breast09 study, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. 'Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% reduction in the risk of disease progression or death when compared to a taxane, trastuzumab, and pertuzumab (THP),' said Tolaney, during her presentation. New First-line Standard? Similar results were observed across all patient subgroups, with no new safety signals, Tolaney said. 'These data suggest that T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer,' she said. The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP). The interim study readout includes only data from the T-DXd-pertuzumab and the taxane plus trastuzumab with pertuzumab groups. Pertuzumab + T-Dxd or Standard of Care? Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients ( P < .00001). Tolaney explained that the study was designed to have an interim analysis for PFS after approximately 399 events across the three arms with at least 277 events for comparison. At the time of the interim analysis, she said, only the TDX-pertuzumab and THP groups met the criteria for superiority, a P -value < .00043, which was not met for the comparison of T-DXd plus placebo to THP. The T-DXd-placebo arm remains blinded until the final progression-free survival analysis, Tolaney said. Twenty-one percent of the patients in the T-DXd-pertuzumab arm had discontinued T-DXd due to adverse events, Tolaney said; 9% of patients elected to continue with trastuzumab and pertuzumab after they discontinued T-DXd. Among hormone receptor-positive patients, 13.5% in the T-DXd-pertuzumab group and 38% in the THP group elected to add endocrine treatment. At the data cutoff, 46% of the T-DXd-pertuzumab patients and 33% of those in the THP group remained on study treatment. Median follow-up duration was 29 months. The treatment effect of T-DXd-pertuzumab became evident early in the study, Tolaney said. Six months after starting treatment, 7% of the T-DXd-pertuzumab group vs 12% of the THP group had progressed. The gap continued to widen over time, she said. 'With 26% of patients still on steady treatment with T-DXd and pertuzumab, it suggests that this median is likely to evolve with further follow-up,' she said. Objective response rates were also higher with T-DXd–pertuzumab, 86% vs 79% with THP, Tolaney said. 'The complete response rate for T-DXd and pertuzumab was 15%, which was almost double what was seen with THP (8.5%),' she said. Response duration was also longer with T-DXd-pertuzumab, with 73% remaining in response at 24 months vs 55% in the THP arm. 'Overall survival data are very immature at this timepoint with just 16% of survival events seen, but you can see that there is an early trend favoring T-DXd plus pertuzumab with a hazard ratio of 0.84,' she said. A similar number of patients in both groups had serious treatment-emergent adverse events: 27% for T-DXd-pertuzumab and 25.1% for THP, which Tolaney said, was consistent with the known toxicity profiles of both agents, with no new toxicities identified. The median duration of treatment in the DESTINY-Breast09 study was 21 months. 'A Pivotal Advancement?' Rebecca Dent, MD, deputy CEO at the National Cancer Center Singapore, called the DESTINY-Breast09 results 'a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statistically significant.' Rebecca Dent, MD HER2-positive metastatic breast cancer was once considered a 'death sentence,' Dent said at a press conference, but now patients can survive on therapy for years, which presents its own challenges. Regarding the T-DXd-plus-pertuzumab regimen, Dent said, 'Is this for all patients at the beginning of their treatment for metastatic disease?' The truth of the matter is we don't know.' Having better biomarkers would provide answers, she said, but for patients with extensive disease with central nervous system metastasis, pertuzumab in combination with other agents 'is clearly your first-line choice.' How to best sequence therapies is another challenge emerging with these evolving treatment regimens, Dent added. 'And then I think finally we do have to appreciate that there are toxicities: One in terms of quality of life but also cost toxicity,' she said. Which Therapeutic Regimen Costs More? Tolaney acknowledged the cost implications of adding pertuzumab to T-DXd, in an interview with Medscape Medical News . 'But I would also note,' Tolaney said, 'that the standard-of-care arm does involve getting continued trastuzumab and pertuzumab therapy.' In the PATINA study, which added palbociclib (Ibrance) to standard maintenance therapy in patients with HER2-positive metastatic breast cancer, the cost profile was similar to those of the treatments used in the newer trial, Tolaney said. 'You are looking at substantial continued cost because we're continuing to suppress the HER2 pathway for years in these patients,' she said. AstraZeneca and Daiichi Sankyo funded the study. Tolaney reported financial relationships with ADi, Ambrx, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Hengrui Pharmaceutical (USA), Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana, NanoString Technologies, Natera, Novartis, OncoPep, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Summit Therapeutics, Systimmune, Tango Therapeutics, Zentalis, Zuellig Pharma, and Zymeworks. Dent reported having financial relationships with AstraZeneca, Daiichi Sankyo/Astra Zeneca, DKSH, Eisai, Gilead Sciences, Merck Sharpe and Dohme, Novartis, Pfizer, and Roche.
Gizmodo
26 minutes ago
- Gizmodo
Amazon Is Going Nuts Before Prime Day, With This Mini Sony Portable Speaker Now Almost Free
For the summer, a good speaker that can be taken anywhere is a must if you're headed to the beach, by the pool or hosting a backyard party with your friends. The problem is, most portable speakers that are actually durable and sound well cost between $200 and $300, well out of most of our price ranges. That's why the Sony SRS-XB100 is such a great value today: This speaker is currently available on Amazon for as little as $38, a discount from its standard price of $59, which already is considerably lower than most other options will run. At a 37% off and all-time low, it's an opportunity to score a top quality portable speaker for about ten times cheaper than usual. See at Amazon Good Sound, Low Price Affordable yet without sacrificing features or quality of sound, the Sony SRS-XB100 is designed to deliver strong and full sound with great bass from a more advanced driver that boosts low tones. From listening to a podcast stream to your favorite summer tunes, sound is crisp and lively, filling a room with low sound. The Sound Diffusion Processor even enhances this experience by diffusing sound evenly, such that anyone within the vicinity can hear the music irrespective of their seating. The speaker is absurdly compact and lightweight, meaning you can carry it around in a bag or grasp it in your hand. It comes with a specially made strap, so you can attach it to your backpack, bike, or pin it up at your campsite. Don't let its minimal dimensions fool you: This speaker is rugged enough for the rigors of outdoor adventures and everyday use. IP67 rated, the speaker is both dust and waterproof and thus can be taken to the poolside, beach, or even for a shower without worrying about being damaged. The new UV coating offers an extra layer of protection, ensuring that the speaker does not get faded off or wear away despite hours of exposure to sunlight. That makes it a reliable companion for summer vacations, travel, and spontaneous gatherings. Apart from up to 16 hours of uninterrupted playback from a single charge, the battery level indicator keeps you informed at all times so you won't be caught off guard. Apart from this, it's easy and fast to recharge using the USB Type-C connection, so you will always be prepared. It's simple to pair your devices with Bluetooth capabilities, and allows you to stream music straight from your phone, tablet, or laptop. You can even pair a second SRS-XB100 for stereo sound for an even more immersive listening experience. The built-in microphone with echo-canceling technology also allows hands-free calling to be clear and convenient, whether answering by the pool or during a group video call. Good sound, durable construction, great battery life, and easy connectivity: Make sure to grab yours before it runs out of stock. See at Amazon
